LENZ Therapeutics has unveiled its national consumer campaign “Make it VIZZable,” enlisting award-winning actor and producer Sarah Jessica Parker as brand ambassador for VIZZ™ (aceclidine ophthalmic solution) 1.44%. The campaign, filmed on location in New York City, showcases Parker’s firsthand experience overcoming age-related blurry near vision without reading glasses. According to LENZ, over 128 million Americans contend with presbyopia, and Parker’s testimonial—detailing tasks like checking her phone, applying makeup and reading scripts—underscores the product’s convenience. Free samples are available through participating eye care providers, and interested patients can locate a prescribing doctor via VIZZ.com.

The CLARITY Phase 3 trial enrolled 250 presbyopic adults and demonstrated that 93% of participants achieved near vision of 20/40 or better within 30 minutes of dosing, with effects lasting up to 10 hours. VIZZ’s mechanism—a predominantly pupil-selective miotic action producing a sub-2 mm pupil to extend depth of focus—generates a pinhole effect without inducing a myopic shift. LENZ reports that participants were able to read fine print on phone screens and price tags without corrective eyewear. The safety profile was favorable: the most common adverse reactions (in more than 5% of subjects) included mild dim vision (16%), instillation site irritation (20%) and headache (13%), all generally transient and self-resolving.

Headquartered in San Diego, LENZ Therapeutics is commercializing VIZZ across the United States via prescription through optometrists and ophthalmologists. The company highlights that adults over age 50 lose, on average, 1.5 lines of near vision every six years, creating a rapidly expanding addressable market as the 45-plus demographic grows. LENZ plans to broaden access through licensing agreements in international territories and to amplify patient awareness with digital outreach across Facebook, Instagram, TikTok, YouTube and LinkedIn. CEO Eef Schimmelpennink emphasizes that VIZZ represents the first FDA-approved eye drop alternative to reading glasses for presbyopia, positioning LENZ to capitalize on an estimated global population of 1.8 billion presbyopes.